FRANKLIN, Tenn.--(BUSINESS WIRE)--MedQuist Holdings Inc. (NASDAQ: MEDH):
Fourth Quarter Highlights
- Total clinical documentation volume increased 37% to 850 million lines
- Adjusted EBITDA increased 66% to $27.6 million, or 25% of net revenues
- Adjusted Net Income per diluted share - adjusted for the IPO and exchange offer up 22% to $0.28
- Percentage of total clinical documentation volume produced offshore and edited post speech recognition reaches 42% and 71%
- Issues performance goals for 2011
Capital Structure and Liquidity Highlights
- Full year free cash flow exceeded 60% of Adjusted EBITDA
- Improved liquidity with new $200 million term loan, $25 million credit facility and $85 million in Senior Notes
- Sale of A-Life Medical and Patient Financial Services generated $32 million in proceeds
- Closed IPO totaling 4.5 million shares, including 3.0 million primary shares and 1.5 million secondary shares
- Completed exchange offers that result in approximately 97% ownership of MedQuist Inc.
The highlights above, as well as the discussion below, contain certain non-GAAP financial measures that, together with applicable GAAP financial measures, we utilize to evaluate the results of our performance. Refer to the section of this release entitled “Non-GAAP Financial Measures” for further discussion, as well as the tables attached to this release that reconcile these non-GAAP financial measures to applicable GAAP financial measures.
MedQuist Holdings Inc. (NASDAQ: MEDH), a leading provider of integrated clinical documentation solutions for the U.S. healthcare industry, announced its financial results for the fourth quarter and full year ended December 31, 2010. The Company’s consolidated statements of operations contained herein give effect to the reclassification of the Patient Financial Services business into discontinued operations.
Fourth Quarter Results
Net revenues increased 29% to $110.5 million for the three months ended December 31, 2010, compared with $85.8 million for the three months ended December 31, 2009, including $29.9 million in net revenues contributed by the acquisition of Spheris in April 2010. Total clinical documentation volume for the fourth quarter of 2010 increased 37% to 850 million lines compared with 620 million lines in the prior-year period. The revenue trend reflects our efforts to offer lower pricing to our customers in exchange for increased offshore production and speech recognition; ensuring higher customer retention at higher margins.
Adjusted EBITDA for the fourth quarter of 2010 improved to $27.6 million, or 25.0% of net revenues, compared with $16.7 million, or 19.5% of net revenues, for the prior-year period. The increase in Adjusted EBITDA and margin is the result of higher utilization of offshore resources and higher percentage of volume edited post speech recognition. Increased volumes from the acquisition of Spheris added to the Company’s scalable platform and allowed the Company to realize $7 million in synergies during the fourth quarter.
Adjusted net income for the fourth quarter of 2010 was $14.4 million, or $0.28 per diluted share - adjusted for the IPO and exchange offer, compared with $11.9 million, or $0.23 per diluted share - adjusted for the IPO and exchange offer, in the prior-year period. Net income attributable to common shareholders for the fourth quarter of 2010 was $1.4 million, or $0.04 per diluted share, compared with $275,000, or $0.01 per diluted share, reported in the prior-year period.
Free cash flow for the fourth quarter of 2010 was $13.5 million compared with $13.1 million in the fourth quarter of 2009.
| Fourth Quarter Operating Metrics | 2010 | 2009 | ||||
| Total clinical documentation volume: | 850 million lines | 620 million lines | ||||
| Transcription volumes processed offshore: | 42% | 39% | ||||
| Transcription volumes edited post speech recognition: | 71% | 53% | ||||
Robert Aquilina, Chairman of MedQuist Holdings, said, “Through our industry leading platform, we are giving our customers the features, customer service capabilities, and cost savings they desire. Our higher volumes have enabled us to leverage the scale of our platform while also realizing the benefits of offshore resources and post speech recognition editing. The acquisition and turnaround of two companies in the last two years speaks to the success of our strategy with a five-fold increase in Adjusted EBITDA during that period and, most recently, the $7 million of synergies gained in the fourth quarter, or $28 million annualized, from the integration of Spheris. We will look to continue this performance in 2011 as well as organic growth derived from a relentless focus on new business.”
Full Year 2010 Results
Net revenues increased 18% to $417.3 million for the year ended December 31, 2010 compared with $353.9 million for the year ended December 31, 2009, including $88 million in net revenues from the acquisition of Spheris in April 2010. Total clinical documentation volume in 2010 increased 24% to 3.1 billion lines compared with 2.5 billion lines in 2009. Revenue trends for 2010 are consistent with the factors cited above for the fourth quarter.
Adjusted EBITDA increased to $85.5 million, or 20.5% of net revenues, for 2010, compared with $59.7 million, or 16.9% of net revenues, for 2009. The increase in Adjusted EBITDA and margin during 2010 is the result of higher utilization of offshore resources and higher percentage of volume edited post speech recognition, as well as increased volumes resulting from the acquisition of Spheris and related synergies. The full year 2010 results only reflect $12 million of Spheris acquisition synergies due to timing of the acquisition, of which $7 million was realized in the fourth quarter.
Adjusted net income for 2010 was $52.3 million, or $1.01 per diluted share - adjusted for the IPO and exchange offer, compared with $39.9 million, or $0.79 per diluted share - adjusted for the IPO and exchange offer, for 2009. Net income attributable to common shareholders for 2010 was $5.8 million, or $0.16 per diluted share, compared with a net loss attributable to common shareholders of $(2.0) million, or $(0.06) per diluted share, for 2009.
Free cash flow for 2010 was $54.5 million compared with $44.2 million in 2009.
| Full Year Operating Metrics | 2010 | 2009 | ||||
| Total clinical documentation volume: | 3.1 billion lines | 2.5 billion lines | ||||
| Transcription volumes processed offshore: | 41% | 35% | ||||
| Transcription volumes edited post speech recognition: | 65% | 48% | ||||
Liquidity and Capital Structure
As of December 31, 2010, the Company had $67 million in cash and $295 million in debt. During the fourth quarter of 2010, the Company entered into a credit agreement consisting of a $200 million term loan along with a $25 million revolving credit facility and borrowed an additional $85 million under a Senior Subordinated Note. Proceeds were used to refinance existing indebtedness and pay a special cash dividend of $53.9 million to shareholders. The Company also improved its liquidity with the sale of two non-strategic businesses during the quarter. In October, the Company completed the sale of its interest in A-Life Medical for cash consideration of $23.6 million of which $4.1 million will be held in escrow until March 2012, resulting in an $8.8 million gain in the fourth quarter. In December, the Company also divested its Patient Financial Services business for total consideration of $14.8 million, resulting in a $525,000 gain in the fourth quarter. In addition to the $5 million scheduled principal amortization, the Company also made an optional $20 million prepayment on its term loan in the first quarter of 2011, thereby satisfying its principal amortization obligations on its term loan through the first quarter of 2012.
Our high level of cash generated as compared to our Adjusted EBITDA reflects our continued ability to utilize our tax attributes to absorb current period taxes. As of December 31, 2010, we had federal net operating loss carry forward amounts of approximately $102 million plus state net operating loss carry forward amounts of approximately $286 million available to help off-set future period taxable income amounts. We also had approximately $194 million of capitalized tax intangibles that will be amortized against operating income in future periods. Utilization of the net operating loss carry forwards and intangible amortization amounts are subject to annual limitations in future years, but are anticipated to result in low cash tax amounts paid in the near term.
Mr. Aquilina, noted, “The proceeds from the IPO and the continued ability to convert Adjusted EBITDA into high levels of free cash flow will allow us to execute on our growth initiatives. Our highly efficient operating model is further enhanced by our significant net operating loss tax carry forwards, the tax amortization of acquired intangibles, and modest capital expenditure requirements.”
On January 27, 2011, the Company changed its name from CBaySystems Holdings Limited to MedQuist Holdings Inc., delisted its common stock from the Alternative Investment Market of the London Stock Exchange (AIM) and redomiciled from a British Virgin Islands company to a Delaware corporation. On February 4, 2011, MedQuist Holdings Inc. listed its shares on the NASDAQ and began trading. MedQuist Holdings Inc. closed its initial U.S. public offering of 3.0 million primary shares of common stock and 1.5 million secondary shares of its common stock on February 9, 2011. The Company received approximately $22.3 million in proceeds, net of the underwriting discount, and incurred approximately $7.5 million in additional fees and expenses associated with the IPO.
On February 15, 2011, MedQuist Holdings Inc. completed a private exchange through which it exchanged MedQuist Holdings Inc. shares for MedQuist Inc. shares and increased its ownership of MedQuist Inc. from 69.5% to 82.2%. The Company initiated a public exchange offer for all remaining shares of MedQuist Inc. on February 3, 2011, which was subsequently completed on March 11, 2011 and brought MedQuist Holdings Inc.’s ownership of MedQuist Inc. to approximately 97%. The Company estimates that it will pay additional fees and expenses associated with the exchange offers of approximately $12.0 million. In accordance with the terms of a memorandum of understanding entered into in connection with the settlement of MedQuist Inc. shareholder litigation and subject to final approval of the settlement by the Court, the remaining issued and outstanding shares of MedQuist Inc. are expected to be exchanged on the same terms as the public exchange in a short-form merger by the end of the second quarter of 2011.
Performance Goals for 2011
The Company expects that volume growth, higher percentage of volume edited using speech recognition technology and produced offshore, growth in Adjusted EBITDA and Adjusted Net Income per share will continue to be the primary metrics for assessing the Company’s performance. With the completion of the recapitalization, the Company is now in a position to implement the full integration of MedQuist Inc. and MedQuist Holdings. To achieve this integration, the Company is evaluating a potential restructuring plan and believes a potential charge could range from $2.5 million to $5.0 million. The restructuring plan will be finalized and implemented throughout 2011 with the full benefit experienced by early 2012.
The Company’s Performance Goals noted below include the expected benefit in the second half of 2011 from additional integration savings and assumes 52.2 million fully diluted common shares outstanding for the year. The Performance Goals exclude any impact from potential acquisitions.
| Total clinical documentation volume: | 3.5 billion to 3.7 billion lines | |||
| Adjusted EBITDA: | $112 million to $116 million | |||
| Adjusted Net Income: | $1.24 to $1.31 per diluted share - adjusted for the IPO and exchange offer | |||
Commenting on the 2011 outlook, Mr. Aquilina added, “We expect to achieve volume growth in 2011 through significant, aggressive sales efforts, and excellent customer service and retention. We will also continue to benefit from the synergies from our successful integration of Spheris, the increase in volume processed offshore and edited post speech recognition, and our plans for achieving additional synergies from the integration of MedQuist Inc. later in the year. While we have made no projections for acquisitions in our outlook, we will continue to explore potential opportunities that create synergies through our lower cost structure, add value to our industry leading platform, and/or extend the range of solutions we provide.”
Investor Conference Call and Web Simulcast
MedQuist Holdings will host a conference call on March 16, 2011, at 9:00 a.m. CT to discuss its results of operations for the fourth quarter of 2010. The number to call for the interactive teleconference is (212) 231-2905. A replay of the conference call will be available through Wednesday, March 23, 2011, by dialing (402) 977-9140 and entering the confirmation number, 21514728.
A live broadcast of MedQuist Holdings quarterly conference call will be available online at the Company's website, www.medquistholdings.com, under Investor Relations or http://www.videonewswire.com/event.asp?id=77420 on March 16, 2011, beginning at 9:00 a.m. CT. The online replay will follow shortly after the call and continue for one year.
About MedQuist Holdings
MedQuist Holdings is a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, and the largest provider by revenue of clinical documentation based on physicians’ dictation of patient interaction, or the physician narrative, in the United States. MedQuist Holdings serves more than 2,400 hospitals, clinics, and physician practices throughout the United States, including 40% of hospitals with more than 500 licensed beds.
MedQuist Holdings’ solutions convert the physician narrative into a high quality and customized electronic record, and enable hospitals, clinics, and physician practices to improve the quality of clinical data as well as accelerate and automate the documentation process. We believe our solutions improve physician productivity and satisfaction, enhance revenue cycle performance, and facilitate the adoption and use of electronic health records. For more information, please visit our website at www.medquistholdings.com.
Forward-Looking Statements
Information provided and statements contained in this press release that are not purely historical, such as statements regarding our 2011 financial and operating performance, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements only speak as of the date of this press release and MedQuist Holdings Inc. assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict, including, without limitation, specific factors discussed herein and in other releases and public filings made by MedQuist Holdings Inc. (including filings by MedQuist Holdings Inc. with the SEC). Although MedQuist Holdings believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, MedQuist Holdings also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
| MedQuist Holdings Inc. and Subsidiaries | ||||||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||||||
| Unaudited | ||||||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||||||
| December 31, | December 31, | |||||||||||||||||||
| 2010 | 2009 | 2010 | 2009 | |||||||||||||||||
| Net revenues | $ | 110,534 | $ | 85,812 | $ | 417,326 | $ | 353,932 | ||||||||||||
| Cost of revenues | 64,308 | 54,254 | 259,194 | 229,701 | ||||||||||||||||
| Gross Profit | 46,226 | 31,558 | 158,132 | 124,231 | ||||||||||||||||
| Operating costs and expenses: | ||||||||||||||||||||
| Selling, general and administrative | 15,398 | 12,504 | 61,062 | 53,089 | ||||||||||||||||
| Research and development | 3,086 | 2,369 | 12,030 | 9,604 | ||||||||||||||||
| Depreciation and amortization | 8,872 | 6,446 | 32,617 | 25,366 | ||||||||||||||||
| Cost of legal proceedings and settlements | 820 | 1,403 | 3,605 | 14,943 | ||||||||||||||||
| Acquistion and integration related charges | 512 | 1,246 | 7,407 | 1,246 | ||||||||||||||||
| Restructuring charges | 1,759 | 2,246 | 3,672 | 2,727 | ||||||||||||||||
| Total operating costs and expenses | 30,447 | 26,214 | 120,393 | 106,975 | ||||||||||||||||
| Operating income | 15,779 | 5,344 | 37,739 | 17,256 | ||||||||||||||||
| Gain on sale of investment | 8,780 | 8,780 | - | |||||||||||||||||
| Equity in income (loss) of affiliated company | 77 | (602 | ) | 693 | 1,933 | |||||||||||||||
| Other income (expense) | (100 | ) | 12 | 460 | 13 | |||||||||||||||
| Loss on extinguishment of debt | (13,525 | ) | - | (13,525 | ) | - | ||||||||||||||
| Interest expense, net | (7,299 | ) | (2,149 | ) | (19,268 | ) | (9,019 | ) | ||||||||||||
| Income from continuing operations before income taxes and noncontrolling interests | 3,712 | 2,605 | 14,879 | 10,183 | ||||||||||||||||
| Income tax provision (benefit) | (2,159 | ) | (221 | ) | (2,312 | ) | 1,012 | |||||||||||||
|
Net income from continuing operations |
$ | 5,871 | $ | 2,826 | $ | 17,191 | $ | 9,171 | ||||||||||||
|
|
||||||||||||||||||||
| Discontinued Operations | ||||||||||||||||||||
| Income (loss) from discontinued Patient Financial Services business, net of tax | 218 | (71 | ) | 556 | (1,351 | ) | ||||||||||||||
| Income (loss) from discontinued operations | 218 | (71 | ) | 556 | (1,351 | ) | ||||||||||||||
| Net income | 6,089 | 2,755 | 17,747 | 7,820 | ||||||||||||||||
| Less: Net income attributable to noncontrolling interests | (4,006 | ) | (1,793 | ) | (9,240 | ) | (7,085 | ) | ||||||||||||
| Net income attributable to MedQuist Holdings Inc. | $ | 2,083 | $ | 962 | $ | 8,507 | $ | 735 | ||||||||||||
| Net income (loss) per common share from continuing operations | ||||||||||||||||||||
| Basic | $ | 0.03 | $ | 0.01 | $ | 0.14 | $ | (0.02 | ) | |||||||||||
| Diluted | $ | 0.03 | $ | 0.01 | $ | 0.14 | $ | (0.02 | ) | |||||||||||
| Net income (loss) per common share from discontinued operations | ||||||||||||||||||||
| Basic | $ | 0.01 | $ | - | $ | 0.02 | $ | (0.04 | ) | |||||||||||
| Diluted | $ | 0.01 | $ | - | $ | 0.02 | $ | (0.04 | ) | |||||||||||
| Net income (loss) per common share attributable to MedQuist Holdings Inc. | ||||||||||||||||||||
| Basic | $ | 0.04 | $ | 0.01 | $ | 0.16 | $ | (0.06 | ) | |||||||||||
| Diluted | $ | 0.04 | $ | 0.01 | $ | 0.16 | $ | (0.06 | ) | |||||||||||
| Weighted average shares outstanding: | ||||||||||||||||||||
| Basic | 35,158 | 35,013 | 35,102 | 34,692 | ||||||||||||||||
| Diluted | 36,370 | 35,013 | 35,954 | 34,692 | ||||||||||||||||
| MedQuist Holdings Inc. and Subsidiaries | ||||||||||||
| Consolidated Balance Sheets | ||||||||||||
| (In thousands) | ||||||||||||
| Unaudited | ||||||||||||
| December 31, | December 31, | |||||||||||
| 2010 | 2009 | |||||||||||
| Assets | ||||||||||||
| Current assets: | ||||||||||||
| Cash and cash equivalents | $ | 66,779 | $ | 29,633 | ||||||||
| Accounts receivable, net of allowance of $1,466 and $1,753, respectively | 82,038 | 53,099 | ||||||||||
| Other current assets | 23,706 | 8,739 | ||||||||||
| Total current assets | 172,523 | 91,471 | ||||||||||
| Property and equipment, net | 23,018 | 19,511 | ||||||||||
| Goodwill | 90,268 | 53,187 | ||||||||||
| Other intangible assets, net | 107,962 | 72,838 | ||||||||||
| Deferred income taxes | 6,896 | 2,495 | ||||||||||
| Other assets | 14,212 | 13,566 | ||||||||||
| Total assets | $ | 414,879 | $ | 253,068 | ||||||||
| Liabilities and Equity | ||||||||||||
| Current liabilities: | ||||||||||||
| Current portion of long term debt | $ | 27,817 | $ | 6,207 | ||||||||
| Accounts payable | 11,358 | 11,191 | ||||||||||
| Accrued expenses and other current liability | 36,917 | 29,803 | ||||||||||
| Accrued compensation | 16,911 | 16,034 | ||||||||||
| Deferred revenue | 10,570 | 9,924 | ||||||||||
| Total current liabilities | 103,574 | 73,159 | ||||||||||
| Long term debt | 266,677 | 101,133 | ||||||||||
| Deferred income taxes | 4,221 | 2,166 | ||||||||||
| Due to related parties | 3,537 | 2,185 | ||||||||||
| Other non-current liabilities | 2,360 | 2,124 | ||||||||||
| Total liabilities | 380,368 | 180,767 | ||||||||||
| Commitments and contingencies | ||||||||||||
| Total equity: | ||||||||||||
|
Preferred stock - $0.10 par value; authorized 25,000 shares; none issued or outstanding |
- | - | ||||||||||
|
Common stock - $0.10 par value; authorized 300,000 shares; 35,158 and 35,013 shares issued and outstanding, respectively |
3,516 | 3,501 | ||||||||||
| Additional paid in capital | 148,265 | 149,339 | ||||||||||
| Accumulated deficit | (107,179 | ) | (115,686 | ) | ||||||||
| Accumulated other comprehensive loss | (663 | ) | (174 | ) | ||||||||
| Total MedQuist Holdings Inc. stockholders' equity | 43,939 | 36,980 | ||||||||||
| Noncontrolling interests | (9,428 | ) | 35,321 | |||||||||
| Total equity | 34,511 | 72,301 | ||||||||||
| Total liabilities and equity | $ | 414,880 | $ | 253,068 | ||||||||
| MedQuist Holdings Inc. and Subsidiaries | ||||||||||
| Consolidated Statements of Cash Flow | ||||||||||
| (In thousands) | ||||||||||
| Unaudited | ||||||||||
|
|
Years ended December 31, |
|||||||||
| 2010 | 2009 | |||||||||
|
Operating activities: |
||||||||||
| Net income | $ | 17,747 | $ | 7,820 | ||||||
| Adjustments to reconcile net income to cash provided by operating activities: | ||||||||||
| Depreciation and amortization | 33,454 | 26,977 | ||||||||
| Gain on sale of investment | (8,780 | ) | - | |||||||
| Equity in income of affiliated company | (693 | ) | (1,933 | ) | ||||||
| Deferred income taxes | (3,566 | ) | 679 | |||||||
| Share based compensation | 764 | 856 | ||||||||
| Provision for doubtful accounts | 1,538 | 2,306 | ||||||||
| Non-cash interest expense | 4,132 | 3,272 | ||||||||
| Loss on extinquishment of debt | 13,525 | - | ||||||||
| Other | (963 | ) | 200 | |||||||
| Changes in operating assets and liabilities: | ||||||||||
| Accounts receivable | (9,962 | ) | 3,816 | |||||||
| Other current assets | (1,858 | ) | 2,185 | |||||||
| Other non-current assets | (495 | ) | (615 | ) | ||||||
| Accounts payable | 981 | 871 | ||||||||
| Accrued expenses | (5,378 | ) | (3,634 | ) | ||||||
| Accrued compensation | (4,244 | ) | 1,904 | |||||||
| Deferred revenue | 569 | (2,128 | ) | |||||||
| Other non-current liabilities | (546 | ) | 94 | |||||||
| Net cash provided by operating activities | $ | 36,225 | $ | 42,670 | ||||||
| Investing activities: | ||||||||||
| Purchase of property and equipment | (7,152 | ) | (6,475 | ) | ||||||
| Proceeds from sale of investments | 19,469 | - | ||||||||
| Purchases of capitalized intangible assets | (7,155 | ) | (2,995 | ) | ||||||
| Proceeds from sale of subsidiaries | 12,547 | - | ||||||||
| Payments for acquisitions and interests in affiliates, net of cash acquired | (99,793 | ) | (2,690 | ) | ||||||
| Net cash used in investing activities | (82,084 | ) | (12,160 | ) | ||||||
| Financing activities: | ||||||||||
| Proceeds from debt | 392,352 | 659 | ||||||||
| Repayment of debt | (229,727 | ) | (28,613 | ) | ||||||
| Dividends paid to noncontrolling interests | (53,913 | ) | (15,256 | ) | ||||||
| Debt issuance costs | (21,607 | ) | (1,201 | ) | ||||||
| Payments related to initial public offering | (3,745 | ) | - | |||||||
| Net cash provided by (used in) financing activities | 83,360 | (44,411 | ) | |||||||
| Effect of exchange rate changes | (355 | ) | 666 | |||||||
| Net increase (decrease) in cash and cash equivalents | 37,146 | (13,235 | ) | |||||||
| Cash and cash equivalents - beginning of period | 29,633 | 42,868 | ||||||||
| Cash and cash equivalents - end of period | $ | 66,779 | $ | 29,633 | ||||||
| MedQuist Holdings Inc. and Subsidiaries | ||||||||||||||||||||
| Reconciliation of Net Income to Adjusted EBITDA | ||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||
| Unaudited | ||||||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||||||
| December 31, | December 31, | |||||||||||||||||||
| 2010 | 2009 | 2010 | 2009 | |||||||||||||||||
| Net income attributable to MedQuist Holdings Inc. | $ | 2,083 | $ | 962 | $ | 8,507 | $ | 735 | ||||||||||||
| Net income attributable to noncontrolling interest | 4,006 | 1,793 | 9,240 | 7,085 | ||||||||||||||||
| (Income) loss from discontinuing operations | (218 | ) | 71 | (556 | ) | 1,351 | ||||||||||||||
| Income tax provision (benefit) | (2,159 | ) | (221 | ) | (2,312 | ) | 1,012 | |||||||||||||
| Interest expense, net | 7,299 | 2,149 | 19,268 | 9,019 | ||||||||||||||||
| Loss on extinguishment of debt | 13,525 | - | 13,525 | - | ||||||||||||||||
| Depreciation and amortization | 8,872 | 6,446 | 32,617 | 25,366 | ||||||||||||||||
| Restructuring charges | 1,759 | 2,246 | 3,672 | 2,727 | ||||||||||||||||
| Acquisition and integration related charges | 512 | 1,246 | 7,407 | 1,246 | ||||||||||||||||
| Cost of legal proceedings and settlements | 820 | 1,403 | 3,605 | 14,943 | ||||||||||||||||
| Accrual reversals | - | - | - | (1,864 | ) | |||||||||||||||
| Gain on sale of investment | (8,780 | ) | - | (8,780 | ) | - | ||||||||||||||
| Equity in (income) loss of affiliated company | (77 | ) | 602 | (693 | ) | (1,933 | ) | |||||||||||||
| Adjusted EBITDA | $ | 27,642 | $ | 16,697 | $ | 85,500 | $ | 59,687 | ||||||||||||
| Adjusted EBITDA as a percentage of net revenues | 25.0 | % | 19.5 | % | 20.5 | % | 16.9 | % | ||||||||||||
| MedQuist Holdings Inc. and Subsidiaries | |||||||||||||||||||||
| Free Cash Flow | |||||||||||||||||||||
| (In thousands) | |||||||||||||||||||||
| Unaudited | |||||||||||||||||||||
| Three Months Ended | Year Ended | ||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||
| 2010 | 2009 | 2010 | 2009 | ||||||||||||||||||
| Adjusted EBITDA | $ | 27,642 | $ | 16,697 | $ | 85,500 | $ | 59,687 | |||||||||||||
|
Less: |
Interest expense, net |
(7,299 | ) | (2,149 | ) | (19,268 | ) | (9,019 | ) | ||||||||||||
|
|
Non-cash interest expense |
803 | - | 4,132 | 3,272 | ||||||||||||||||
|
|
Capital expenditures (including internal-use software) |
(4,687 | ) | (2,331 | ) | (14,307 | ) | (9,470 | ) | ||||||||||||
|
|
Tax (provision) benefit |
2,159 | 221 | 2,312 | (1,012 | ) | |||||||||||||||
|
Add: |
Deferred tax provision (benefit) |
(5,072 | ) | 693 | (3,903 | ) | 695 | ||||||||||||||
| Free Cash Flow | $ | 13,546 | $ | 13,131 | $ | 54,466 | $ | 44,153 | |||||||||||||
| MedQuist Holdings Inc. and Subsidiaries | ||||||||||||||||||||||
| Adjusted Net Income | ||||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||||
| Unaudited | ||||||||||||||||||||||
| Adjusted Net Income: | ||||||||||||||||||||||
| Adjusted EBITDA | $ | 27,642 | $ | 16,697 | $ | 85,500 | $ | 59,687 | ||||||||||||||
| Amortization (excluding acquired intangibles) | (3,869 | ) | (3,534 | ) | (16,482 | ) | (13,686 | ) | ||||||||||||||
|
|
Cash interest (total expenses less non-cash) |
(6,496 | ) | (2,149 | ) | (15,137 | ) | (5,747 | ) | |||||||||||||
|
|
Current tax provision (benefit) |
(2,913 | ) | 914 | (1,590 | ) | (333 | ) | ||||||||||||||
| Adjusted Net Income | $ | 14,364 | $ | 11,928 | $ | 52,291 | $ | 39,921 | ||||||||||||||
| Adjusted Net Income Per Share - Adjusted for IPO and Exchange Offer: | ||||||||||||||||||||||
| Basic (a) | $ | 0.28 | $ | 0.23 | $ | 1.03 | $ | 0.79 | ||||||||||||||
| Diluted (a) | $ | 0.28 | $ | 0.23 | $ | 1.01 | $ | 0.79 | ||||||||||||||
| (a) Based on proforma shares outstanding for the IPO and Exchange Offer. See Share Calculation below. | ||||||||||||||||||||||
| MedQuist Holdings Inc. and Subsidiaries | |||||||||||||
| Share Calculation | |||||||||||||
| (In thousands) | |||||||||||||
| Unaudited | |||||||||||||
| Three Months Ended | Year Ended | ||||||||||||
| December 31, | December 31, | ||||||||||||
| 2010 | 2009 | 2010 | 2009 | ||||||||||
| MedQuist Holdings Shares | |||||||||||||
| Basic outstanding | 35,158 | 35,013 | 35,012 | 34,692 | |||||||||
| Effect of diluted options | 1,212 | - | 942 | - | |||||||||
| Diluted shares | 36,370 | 35,013 | 35,954 | 34,692 | |||||||||
| MedQuist, Inc. Shares | |||||||||||||
| Basic outstanding | 37,556 | 37,556 | 37,556 | 37,556 | |||||||||
| Effect of diluted options | 34 | - | - | - | |||||||||
| Diluted shares | 37,590 | 37,556 | 37,556 | 37,556 | |||||||||
| Minority interest - basic (1) | 11,455 | 11,455 | 11,455 | 11,455 | |||||||||
| Minority interest - diluted (1) | 11,465 | 11,455 | 11,455 | 11,455 | |||||||||
| Proforma Shares Outstanding for Exchange Offer | |||||||||||||
| Basic | 46,613 | 46,468 | 46,467 | 46,147 | |||||||||
| Diluted | 47,835 | 46,468 | 47,409 | 46,147 | |||||||||
| Proforma Shares Outstanding for IPO and Exchange Offer | |||||||||||||
| Basic | 50,932 | 50,787 | 50,786 | 50,466 | |||||||||
| Fully Diluted | 52,124 | 50,787 | 51,728 | 50,466 | |||||||||
| (1) Assumes the issuance of our common stock in exchange for shares of MedQuist Inc. common stock pursuant to terms of private and public exchange offers, which will increase our ownership in MedQuist Inc. from 69.5% to 100%. We have completed our exchange offers, and we currently own approximately 97% of MedQuist Inc. | |||||||||||||
Total Clinical Documentation Volume
Management believes that total clinical documentation volume is an important measure of the Company’s operating results. Total clinical documentation volume is defined as total lines processed on our clinical documentation platforms and/or transcribed or edited by our personnel.
Non-GAAP Financial Measures
In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, MedQuist Holdings Inc. has provided certain non-GAAP financial measures to help evaluate the results of our performance. The Company believes that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing the Company’s ongoing business and operating performance. The Company believes that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the Company’s financial results in the way that management views financial results. The tables attached to this press release include a reconciliation of these historical non-GAAP financial measures to the most directly comparable GAAP financial measures.
We also present Adjusted EBITDA and Adjusted Net Income on a forward-looking basis as part of our Performance Goals for 2011. We are unable to present a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because management cannot predict, with sufficient reliability, contingencies relating to potential changes in tax valuation allowances, potential changes to customer accommodation accruals, potential restructuring impacts, contingencies related to past and future acquisitions, and changes in fair values of our derivative instruments, all of which are difficult to estimate primarily due to dependencies on future events.
Adjusted EBITDA
Adjusted EBITDA, a non-GAAP financial measure, is defined by the Company as Net Income excluding taxes, interest, equity in income of an affiliated company, depreciation, amortization, cost of legal proceedings and settlements, acquisition related charges, restructuring charges and certain non-recurring accrual reversals.
Management believes Adjusted EBITDA is useful as a supplemental measures of the Company's financial results because it removes costs not related to the Company's operating performance. Management believes that Adjusted EBITDA should be considered in addition to, but not as a substitute for items presented in accordance with GAAP that are presented in this press release. A reconciliation of Net income to Adjusted EBITDA is provided above.
Free Cash Flow
Free Cash Flow, a non-GAAP financial measure, is defined by the Company as Adjusted EBITDA less interest expense (net of non-cash interest), less capital expenditures (including capitalized software development costs), and less current tax provision. Management believes that utilization of Free Cash Flow is an important non-GAAP measure of the Company’s ability to convert operating results into cash.
Adjusted Net Income
Adjusted Net Income, a non-GAAP financial measure, is defined by the Company as Adjusted EBITDA less amortization expense (net of amortization related to acquired intangibles), less interest expense (net of non-cash interest), and less current tax provision. We measure Adjusted Net Income based on Proforma Shares Outstanding (see below). Management believes that utilization of Adjusted Net Income is an important non-GAAP financial measure of our normalized operating results.
Proforma Shares Outstanding for Exchange Offer
For purposes of evaluating our results on per-share metrics, many of our computations utilize proforma share computations. Our measure of proforma shares includes our Basic and Diluted share computations utilized for GAAP purposes, plus our estimate of the impacts of minority interest shares outstanding of 11.5 million shares.
Proforma Shares Outstanding for Initial Public Offering and Exchange Offer
For purposes of evaluating our results on per-share metrics, many of our computations utilize proforma share computations. Our measure of proforma shares include our Basic and Diluted share computations utilized for GAAP purposes, plus our estimate of the impacts of minority interest shares outstanding of 11.5 million shares and 3.0 million primary shares issued by us in our initial public offering as well as 1.3 million other shares issued after December 31, 2010.